Heather Wray

1.2k total citations · 1 hit paper
28 papers, 894 citations indexed

About

Heather Wray is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Heather Wray has authored 28 papers receiving a total of 894 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 7 papers in Physiology. Recurrent topics in Heather Wray's work include Asthma and respiratory diseases (6 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers) and Chemokine receptors and signaling (4 papers). Heather Wray is often cited by papers focused on Asthma and respiratory diseases (6 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers) and Chemokine receptors and signaling (4 papers). Heather Wray collaborates with scholars based in United Kingdom, Sweden and United States. Heather Wray's co-authors include Arthur Selzer, Ian R. Wilding, Patricia A. Harris, Simon Bailey, Nicola J. Menzies‐Gow, Jonathan Elliott, Bengt Larsson, Marie Cullberg, Henrik Watz and Millie Wang and has published in prestigious journals such as Circulation, European Respiratory Journal and The American Journal of Gastroenterology.

In The Last Decade

Heather Wray

28 papers receiving 831 citations

Hit Papers

Quinidine Syncope 1964 2026 1984 2005 1964 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heather Wray United Kingdom 12 415 228 161 117 104 28 894
Isolde Seiden‐Long Canada 13 101 0.2× 154 0.7× 48 0.3× 69 0.6× 16 0.2× 33 504
F. Goodale United States 15 158 0.4× 67 0.3× 156 1.0× 41 0.4× 65 0.6× 50 704
Shang‐Jyh Kao Taiwan 14 67 0.2× 193 0.8× 360 2.2× 99 0.8× 84 0.8× 27 783
Hongmei Wang China 14 60 0.1× 156 0.7× 85 0.5× 72 0.6× 44 0.4× 69 592
S. Barbier France 9 284 0.7× 56 0.2× 40 0.2× 87 0.7× 150 1.4× 11 1.0k
William T. Newton United States 13 32 0.1× 112 0.5× 122 0.8× 40 0.3× 85 0.8× 40 678
P J Richardson United Kingdom 15 499 1.2× 184 0.8× 41 0.3× 25 0.2× 33 0.3× 34 778
E. Amundsen Norway 17 51 0.1× 116 0.5× 129 0.8× 71 0.6× 81 0.8× 67 764
Tracey J. Wright United Kingdom 8 97 0.2× 147 0.6× 141 0.9× 75 0.6× 139 1.3× 9 764
Johannes Aufenanger Germany 14 52 0.1× 104 0.5× 32 0.2× 58 0.5× 80 0.8× 38 584

Countries citing papers authored by Heather Wray

Since Specialization
Citations

This map shows the geographic impact of Heather Wray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Wray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Wray more than expected).

Fields of papers citing papers by Heather Wray

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather Wray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Wray. The network helps show where Heather Wray may publish in the future.

Co-authorship network of co-authors of Heather Wray

This figure shows the co-authorship network connecting the top 25 collaborators of Heather Wray. A scholar is included among the top collaborators of Heather Wray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather Wray. Heather Wray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Cullberg, Marie, Cecilia Arfvidsson, Bengt Larsson, et al.. (2018). Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers. Drugs in R&D. 18(2). 149–159. 19 indexed citations
3.
Brody, Robert S., Charles Liss, Heather Wray, et al.. (2017). Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union. International Clinical Psychopharmacology. 33(2). 59–65. 1 indexed citations
4.
Förster, Karin, Anneliese Linnhoff, Beatrix Bálint, et al.. (2015). The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulmonary Pharmacology & Therapeutics. 31. 36–41. 73 indexed citations
5.
Soyza, Anthony De, Ian Pavord, J.S. Elborn, et al.. (2015). A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. European Respiratory Journal. 46(4). 1021–1032. 76 indexed citations
6.
Brody, Robert S., Charles Liss, Heather Wray, et al.. (2015). Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine. International Clinical Psychopharmacology. 31(1). 34–41. 9 indexed citations
7.
Cullberg, Marie, Heather Wray, & Bengt Larsson. (2014). Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist. European Respiratory Journal. 44(Suppl 58). P961–P961. 1 indexed citations
8.
Menzies‐Gow, Nicola J., Heather Wray, Simon Bailey, Patricia A. Harris, & Jonathan Elliott. (2014). The effect of tumour necrosis factor-α and insulin on equine digital blood vessel function in vitro. Inflammation Research. 63(8). 637–647. 2 indexed citations
9.
Pavord, Ian, Anthony De Soyza, J.S. Elborn, et al.. (2013). Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. European Respiratory Journal. 42(Suppl 57). P1593–P1593. 7 indexed citations
10.
Dahl, Ronald, Ingrid Louise Titlestad, Ari Lindqvist, et al.. (2012). Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial. Pulmonary Pharmacology & Therapeutics. 25(2). 169–177. 59 indexed citations
11.
Magnussen, H, Henrik Watz, Anne Kirsten, et al.. (2011). Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial. Pulmonary Pharmacology & Therapeutics. 24(5). 563–570. 26 indexed citations
13.
14.
Wilding, Ian R., et al.. (2004). In Vivo Disintegration Profiles of Encapsulated and Nonencapsulated Sumatriptan: Gamma Scintigraphy in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(1). 101–105. 4 indexed citations
15.
Rohatagi, Shashank, Sunny Chapel, Stéphane Kirkesseli, et al.. (2004). Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler. American Journal of Therapeutics. 11(2). 103–113. 5 indexed citations
16.
Wilding, Ian R., et al.. (2003). Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects. Alimentary Pharmacology & Therapeutics. 17(9). 1153–1162. 39 indexed citations
18.
Connor, Alyson, Heather Wray, Jeremy J. Cottrell, & Ian R. Wilding. (2001). A scintigraphic study to investigate the potential for altered gut distribution of loperamide from a loperamide–simethicone formulation in man. European Journal of Pharmaceutical Sciences. 13(4). 369–374. 12 indexed citations
19.
Waterhouse, J C, et al.. (1992). Comparative Assessment of a New Breath-Actuated Inhaler in Patients with Reversible Airways Obstruction. Respiration. 59(3). 155–158. 11 indexed citations
20.
Selzer, Arthur & Heather Wray. (1964). Quinidine Syncope. Circulation. 30(1). 17–26. 428 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026